NewAmsterdam Pharma Company (NAMS) Stock Forecast, Price Target & Predictions
NAMS Stock Forecast
NewAmsterdam Pharma Company stock forecast is as follows: an average price target of $36.50 (represents a 104.83% upside from NAMS’s last price of $17.82) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
NAMS Price Target
The average price target for NewAmsterdam Pharma Company (NAMS) is $36.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $36.00. This represents a potential 104.83% upside from NAMS's last price of $17.82.
NAMS Analyst Ratings
According to 3 Wall Street analysts, NewAmsterdam Pharma Company's rating consensus is 'Buy'. The analyst rating breakdown for NAMS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NewAmsterdam Pharma Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Yasmeen Rahimi | Piper Sandler | $37.00 | $15.95 | 131.97% | 107.63% |
| Aug 28, 2024 | Serge Belanger | Needham | $36.00 | $16.77 | 114.67% | 102.02% |
The latest NewAmsterdam Pharma Company stock forecast, released on Sep 23, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $37.00, which represents a 131.97% increase from the stock price at the time of the forecast ($15.95), and a 107.63% increase from NAMS last price ($17.82).
NewAmsterdam Pharma Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $36.50 | $36.50 |
| Last Closing Price | $17.82 | $17.82 | $17.82 |
| Upside/Downside | -100.00% | 104.83% | 104.83% |
In the current month, the average price target of NewAmsterdam Pharma Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NewAmsterdam Pharma Company's last price of $17.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 23, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2024 | Needham | Buy | Mixed | Initialise |
| Aug 28, 2024 | Needham | - | Buy | Initialise |
| Aug 27, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 15, 2024 | Cowen & Co. | - | Buy | Initialise |
NewAmsterdam Pharma Company's last stock rating was published by Piper Sandler on Oct 21, 2024. The company gave NAMS a "Overweight" rating, the same as its previous rate.
NewAmsterdam Pharma Company Financial Forecast
NewAmsterdam Pharma Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $1.28M | $1.39M | $1.51M | $1.65M | $4.24M | $1.87M | $1.21M | $1.62M | $2.89M |
| High Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $1.28M | $1.39M | $1.51M | $1.65M | $4.24M | $3.04M | $1.25M | $1.66M | $3.12M |
| Low Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $1.28M | $1.39M | $1.51M | $1.65M | $4.24M | $699.83K | $1.16M | $1.57M | $2.65M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAMS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NewAmsterdam Pharma Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $307.86K | $335.26K | $365.10K | $397.60K | $1.02M | $451.84K | $291.09K | $390.74K | $696.73K |
| High Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $307.86K | $335.26K | $365.10K | $397.60K | $1.02M | $734.77K | $301.02K | $401.43K | $752.03K |
| Low Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $307.86K | $335.26K | $365.10K | $397.60K | $1.02M | $168.91K | $281.16K | $380.05K | $639.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict NAMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NewAmsterdam Pharma Company's previous annual EBITDA (undefined) of $NaN.
NewAmsterdam Pharma Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-28.99M | $-25.54M | $-23.88M | $-23.80M | $-30.80M | $-32.69M | $-34.39M | $-37.86M | $-41.12M | $-42.35M | $-50.91M | $-54.46M | $-50.34M |
| High Forecast | $-28.99M | $-25.54M | $-23.88M | $-23.80M | $-30.80M | $-32.69M | $-34.39M | $-37.86M | $-41.12M | $-39.70M | $-50.91M | $-54.46M | $-46.00M |
| Low Forecast | $-28.99M | $-25.54M | $-23.88M | $-23.80M | $-30.80M | $-32.69M | $-34.39M | $-37.86M | $-41.12M | $-46.76M | $-50.91M | $-54.46M | $-58.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NewAmsterdam Pharma Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.53M | $1.09M | $656.82K | $328.41K | $1.55M | $1.69M | $1.84M | $2.00M | $5.16M | $2.27M | $1.47M | $1.97M | $3.51M |
| High Forecast | $1.53M | $1.09M | $656.82K | $328.41K | $1.55M | $1.69M | $1.84M | $2.00M | $5.16M | $3.70M | $1.52M | $2.02M | $3.79M |
| Low Forecast | $1.53M | $1.09M | $656.82K | $328.41K | $1.55M | $1.69M | $1.84M | $2.00M | $5.16M | $850.44K | $1.42M | $1.91M | $3.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NAMS last annual SG&A of $NaN (undefined).
NewAmsterdam Pharma Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.31 | $-0.27 | $-0.25 | $-0.25 | $-0.33 | $-0.35 | $-0.36 | $-0.40 | $-0.43 | $-0.45 | $-0.54 | $-0.57 | $-0.53 |
| High Forecast | $-0.31 | $-0.27 | $-0.25 | $-0.25 | $-0.33 | $-0.35 | $-0.36 | $-0.40 | $-0.43 | $-0.42 | $-0.54 | $-0.57 | $-0.49 |
| Low Forecast | $-0.31 | $-0.27 | $-0.25 | $-0.25 | $-0.33 | $-0.35 | $-0.36 | $-0.40 | $-0.43 | $-0.49 | $-0.54 | $-0.57 | $-0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, NewAmsterdam Pharma Company's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAMS previous annual EPS of $NaN (undefined).
NewAmsterdam Pharma Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.75 | $36.00 | 1209.09% | Buy |
| MOLN | Molecular Partners | $6.12 | $29.00 | 373.86% | Buy |
| PEPG | PepGen | $6.48 | $29.50 | 355.25% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.84 | $6.00 | 226.09% | Buy |
| CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
| PRTC | PureTech Health | $20.83 | $57.00 | 173.64% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| RZLT | Rezolute | $5.50 | $13.50 | 145.45% | Buy |
| MLYS | Mineralys Therapeutics | $13.45 | $30.00 | 123.05% | Buy |
| NAMS | NewAmsterdam Pharma Company | $17.82 | $36.50 | 104.83% | Buy |
| REPL | Replimune Group | $11.90 | $24.20 | 103.36% | Buy |
| CGEM | Cullinan Oncology | $15.78 | $31.50 | 99.62% | Buy |
| MRUS | Merus | $50.30 | $77.13 | 53.34% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.69 | $70.14 | 23.73% | Buy |
| JANX | Janux Therapeutics | $54.39 | $61.20 | 12.52% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
NAMS Forecast FAQ
Is NewAmsterdam Pharma Company a good buy?
Yes, according to 3 Wall Street analysts, NewAmsterdam Pharma Company (NAMS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of NAMS's total ratings.
What is NAMS's price target?
NewAmsterdam Pharma Company (NAMS) average price target is $36.5 with a range of $36 to $37, implying a 104.83% from its last price of $17.82. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NewAmsterdam Pharma Company stock go up soon?
According to Wall Street analysts' prediction for NAMS stock, the company can go up by 104.83% (from the last price of $17.82 to the average price target of $36.5), up by 107.63% based on the highest stock price target, and up by 102.02% based on the lowest stock price target.
Can NewAmsterdam Pharma Company stock reach $30?
NAMS's average twelve months analyst stock price target of $36.5 supports the claim that NewAmsterdam Pharma Company can reach $30 in the near future.
What are NewAmsterdam Pharma Company's analysts' financial forecasts?
NewAmsterdam Pharma Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.82M (high $5.82M, low $5.82M), average EBITDA is $1.41M (high $1.41M, low $1.41M), average net income is $-136M (high $-136M, low $-136M), average SG&A $7.08M (high $7.08M, low $7.08M), and average EPS is $-1.433 (high $-1.433, low $-1.433). NAMS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.97M (high $2.97M, low $2.97M), average EBITDA is $717.51K (high $717.51K, low $717.51K), average net income is $-102M (high $-102M, low $-102M), average SG&A $3.61M (high $3.61M, low $3.61M), and average EPS is $-1.079 (high $-1.079, low $-1.079).
Did the NAMS's actual financial results beat the analysts' financial forecasts?
Based on NewAmsterdam Pharma Company's last annual report (Dec 2023), the company's revenue was $14.09M, beating the average analysts forecast of $2.89M by 388.11%. Apple's EBITDA was $0, missing the average prediction of $696.73K by -100.00%. The company's net income was $0, missing the average estimation of $-50.34M by -100.00%. Apple's SG&A was $37.63M, beating the average forecast of $3.51M by 972.80%. Lastly, the company's EPS was $-2.15, beating the average prediction of $-0.532 by 304.51%.